Ilunoc­i­tinib CAS 1187594-14-4

• Iden­ti­fi­ca­tion
• Prop­er­ties
• Safe­ty Data
• Spec­i­fi­ca­tions & Oth­er Information
• Links
• Quick Inquiry

Iden­ti­fi­ca­tion

CAS Number

1187594-14-4

Name

Ilunoc­i­tinib

Syn­onyms

{1-(Cyclopropylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidinyl}acetonitril [Ger­man] [ACD/IUPAC Name]
{1-(Cyclopropylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidinyl}acetonitrile [ACD/IUPAC Name]
{1-(Cyclopropylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azétidinyl}acétonitrile [French] [ACD/IUPAC Name]
3-Aze­­tidineace­­toni­trile, 1-(cyclopropylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]- [ACD/​Index Name]
1187594-14-4 [RN]
2-[1-cyclopropylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
Ilunoc­i­tinib

SMILES

N#CCC1(CN(C1)S(=O)(=O)C1CC1)N1C=C(C=N1)C1N=CN=C2NC=CC=12

Std­InChI

InChI=1S/C17H17N7O2S/c18-5-4-17(9-23(10-17)27(25,26)13-1-2-13)24-8-12(7-22-24)15-14-3-6-19-16(14)21-11-20-15/h3,6-8,11,13H,1-2,4,9-10H2,(H,19,20,21)

Std­InChIKey

RVOUEXFKIYN­ODQ-UHF­F­­FAOYSA-N

Mol­e­c­u­lar Formula

C₁₇H₁₇N₇O₂S

Mol­e­c­u­lar Weight

383.428

Prop­er­ties

Appear­ance

White pow­der

Safe­ty Data

Sym­bol

Sig­nal Word

Warn­ing

RIDADR 

NONH for all modes of transport

WGK Germany

3

MSDS Download

Spec­i­fi­ca­tions and Oth­er Infor­ma­tion of Our Ilunoc­i­tinib CAS 1187594-14-4

Iden­ti­fi­ca­tion Methods

Shelf Life

1 year

Stor­age

Store at 2~8°C, away from light.

Known Appli­ca­tion

Ilunoc­i­tinib is a safe, effec­tive, and con­ve­nient Janus kinase (JAK) inhibitor specif­i­cal­ly designed to man­age pru­ri­tus (itch­i­ness) asso­ci­at­ed with aller­gic der­mati­tis, as well as to con­trol atopic der­mati­tis (AD) in dogs aged 12 months and old­er. As a JAK inhibitor, Ilunoc­i­tinib works by inter­fer­ing with the JAK-STAT sig­nal­ing path­way, which is crit­i­cal in medi­at­ing inflam­ma­tion and immune respons­es in con­di­tions like aller­gic and atopic der­mati­tis. By inhibit­ing this path­way, Ilunoc­i­tinib helps to reduce inflam­ma­tion and alle­vi­ate the intense itch­ing that often accom­pa­nies these conditions.

Atopic der­mati­tis in dogs is a chron­ic skin dis­ease that can cause severe dis­com­fort due to per­sis­tent itch­ing and inflam­ma­tion, lead­ing to skin lesions, infec­tions, and a decreased qual­i­ty of life. Tra­di­tion­al treat­ments, such as cor­ti­cos­teroids, often come with long-term side effects, mak­ing the devel­op­ment of tar­get­ed ther­a­pies like Ilunoc­i­tinib a sig­nif­i­cant advance­ment in vet­eri­nary medicine.

Ilunoc­i­tinib offers a more tar­get­ed approach to man­ag­ing the dis­ease by direct­ly inhibit­ing the path­ways involved in the inflam­ma­to­ry response with­out broad­ly sup­press­ing the immune sys­tem. Its safe­ty pro­file and ease of admin­is­tra­tion make it a prac­ti­cal option for long-term man­age­ment, improv­ing the well-being of affect­ed dogs and offer­ing relief from the bur­dens of chron­ic dermatitis.

Gen­er­al View of Documents

Links

This prod­uct is devel­oped by our R&D com­pa­ny Cam­ing Phar­ma­ceu­ti­cal Lim­it­ed (http://​www​.cam​ing​.com/).

Quick Inquiry

Fill out our inquiry form and one of our experts will be in touch with you shortly.